18. 脊髄小脳変性症（多系統萎縮症を除く。） Spinocerebellar degeneration Clinical trials / Disease details

臨床試験数 : 76 /  薬物数 : 98 - (DrugBank : 31) / 標的遺伝子数 : 44 - 標的パスウェイ数 : 65

  
3 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT05579691
(ClinicalTrials.gov)		September 21, 20225/10/2022A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's AtaxiaA Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Exploration Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CTI-1601 in Adult Subjects With Friedreich's AtaxiaFriedreich AtaxiaBiological: CTI-1601;Other: PlaceboLarimar Therapeutics, Inc.NULLRecruiting18 YearsN/AAll15Phase 2United States
2NCT04519567
(ClinicalTrials.gov)		July 31, 202017/8/2020Multiple Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's AtaxiaA Phase 1 Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CTI-1601 Versus Placebo in Subjects With Friedreich's AtaxiaFriedreich AtaxiaBiological: CTI-1601;Biological: PlaceboLarimar Therapeutics, Inc.Veristat, Inc.;Metrum Research Group, LLCCompleted18 YearsN/AAll27Phase 1United States
3NCT04176991
(ClinicalTrials.gov)		December 11, 201914/11/2019Single Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's AtaxiaA Phase 1 Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CTI-1601 Versus Placebo in Subjects With Friedreich's AtaxiaFriedreich AtaxiaBiological: CTI-1601;Biological: PlaceboLarimar Therapeutics, Inc.Veristat, Inc.;Metrum Research Group, LLCCompleted18 YearsN/AAll28Phase 1United States